The stock of Exact Sciences Corp (EXAS) has seen a 1.60% increase in the past week, with a -8.80% drop in the past month, and a -17.55% decrease in the past quarter. The volatility ratio for the week is 3.16%, and the volatility levels for the past 30 days are at 3.33% for EXAS. The simple moving average for the past 20 days is -3.04% for EXAS’s stock, with a -1.70% simple moving average for the past 200 days.
Is It Worth Investing in Exact Sciences Corp (NASDAQ: EXAS) Right Now?
EXAS has 36-month beta value of 1.24. Analysts have mixed views on the stock, with 17 analysts rating it as a “buy,” 3 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for EXAS is 182.43M, and currently, short sellers hold a 6.14% ratio of that float. The average trading volume of EXAS on January 08, 2025 was 2.32M shares.
EXAS) stock’s latest price update
Exact Sciences Corp (NASDAQ: EXAS) has experienced a decline in its stock price by -1.21 compared to its previous closing price of 57.80. However, the company has seen a gain of 1.60% in its stock price over the last five trading days. businesswire.com reported 2025-01-02 that MADISON, Wis.–(BUSINESS WIRE)–Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. J.P. Morgan Healthcare Conference, San Francisco Presentation followed by Q&A on Monday, January 13, 2025 at 1:30 p.m. ET The webcast can be accessed in the investor relations section of Exact Sciences’ website at www.exactsciences.
Analysts’ Opinion of EXAS
Many brokerage firms have already submitted their reports for EXAS stocks, with Wells Fargo repeating the rating for EXAS by listing it as a “Overweight.” The predicted price for EXAS in the upcoming period, according to Wells Fargo is $75 based on the research report published on August 28, 2024 of the previous year 2024.
Scotiabank, on the other hand, stated in their research note that they expect to see EXAS reach a price target of $70. The rating they have provided for EXAS stocks is “Sector Outperform” according to the report published on June 27th, 2024.
Jefferies gave a rating of “Buy” to EXAS, setting the target price at $75 in the report published on June 03rd of the previous year.
EXAS Trading at -3.62% from the 50-Day Moving Average
After a stumble in the market that brought EXAS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.28% of loss for the given period.
Volatility was left at 3.33%, however, over the last 30 days, the volatility rate increased by 3.16%, as shares sank -8.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.73% lower at present.
During the last 5 trading sessions, EXAS rose by +1.60%, which changed the moving average for the period of 200-days by -7.90% in comparison to the 20-day moving average, which settled at $58.89. In addition, Exact Sciences Corp saw 1.62% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EXAS starting from Conroy Kevin T, who purchase 19,500 shares at the price of $51.35 back on Nov 13 ’24. After this action, Conroy Kevin T now owns 1,074,191 shares of Exact Sciences Corp, valued at $1,001,325 using the latest closing price.
Baranick Brian, the EVP, GM, Precision Oncology of Exact Sciences Corp, sale 929 shares at $70.00 during a trade that took place back on Oct 08 ’24, which means that Baranick Brian is holding 12,758 shares at $65,030 based on the most recent closing price.
Stock Fundamentals for EXAS
Current profitability levels for the company are sitting at:
- -0.09 for the present operating margin
- 0.72 for the gross margin
The net margin for Exact Sciences Corp stands at -0.08. The total capital return value is set at -0.04. Equity return is now at value -6.76, with -3.25 for asset returns.
Based on Exact Sciences Corp (EXAS), the company’s capital structure generated 0.44 points at debt to capital in total, while cash flow to debt ratio is standing at 0.09. The debt to equity ratio resting at 0.8. The interest coverage ratio of the stock is -10.02.
Currently, EBITDA for the company is 41.88 million with net debt to EBITDA at 82.57. When we switch over and look at the enterprise to sales, we see a ratio of 4.73. The receivables turnover for the company is 10.17for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.12.
Conclusion
To put it simply, Exact Sciences Corp (EXAS) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
